Education
About Us
Working with TipRanks
Follow Us
Oxford BioMedica plc (OXBDF)
OTHER OTC:OXBDF
OXBDF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.15 - $5.95
Previous CloseN/A
Volume1.00K
Average Volume (3M)35.00
Market Cap
$454.22M
Enterprise Value$412.54M
Total Cash (Recent Filing)$60.65M
Total Debt (Recent Filing)£108.76M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Apr 09, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding106,093,860
10 Day Avg. Volume50
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)6.38
Price to Sales (P/S)0.00
P/FCF Ratio-6.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.81Price Target Upside99.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Oxford BioMedica News
PremiumCompany Announcements
Oxford BioMedica Achieves Full Ownership of US Subsidiary
PremiumCompany Announcements
Oxford Biomedica Director Increases Stake with Share Purchase
PremiumCompany Announcements
Oxford Biomedica Announces AGM Results and Board Changes
PremiumCompany Announcements
Oxford Biomedica Reports Strong Momentum and Reaffirms Financial GuidancePremiumCompany Announcements
Oxford BioMedica Announces Change in Voting RightsBulls Say, Bears Say
Bulls Say
Future ProfitabilityOXB is on track to deliver EBITDA profitability in 2025, supported by a healthy contracted order book.
Market PositionOXB is well-placed to capture future growth in the CGT space while currently delivering strong growth.
Revenue GrowthOXB delivered revenues of £128.8m, in line with its January trading update and previous guidance, representing 44% growth YoY.
Bears Say
Macroeconomic ConcernsThere is a level of caution on the outlook due to uncertain macroeconomic headwinds and a tight funding environment.
Options Prices
Currently, No data available
---
Ownership Overview
<0.01% Insiders
0.29% Mutual Funds
2.15% Other Institutional Investors
97.47% Public Companies and
Individual Investors
OXBDF FAQ
What was Oxford BioMedica plc’s price range in the past 12 months?
Oxford BioMedica plc lowest stock price was $3.15 and its highest was $5.95 in the past 12 months.
What is Oxford BioMedica plc’s market cap?
Oxford BioMedica plc’s market cap is $454.22M.
When is Oxford BioMedica plc’s upcoming earnings report date?
Oxford BioMedica plc’s upcoming earnings report date is Apr 09, 2025 which is 82 days ago.
How were Oxford BioMedica plc’s earnings last quarter?
Oxford BioMedica plc released its earnings results on Sep 23, 2024. The company reported -$0.411 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.036.
Is Oxford BioMedica plc overvalued?
According to Wall Street analysts Oxford BioMedica plc’s price is currently Undervalued.
Does Oxford BioMedica plc pay dividends?
Oxford BioMedica plc does not currently pay dividends.
What is Oxford BioMedica plc’s EPS estimate?
Oxford BioMedica plc’s EPS estimate is -0.1.
How many shares outstanding does Oxford BioMedica plc have?
Oxford BioMedica plc has 106,093,860 shares outstanding.
What happened to Oxford BioMedica plc’s price movement after its last earnings report?
Oxford BioMedica plc reported an EPS of -$0.411 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Oxford BioMedica plc?
Currently, no hedge funds are holding shares in OXBDF
Oxford BioMedica Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.81 (99.77% Upside)
$8.81 (99.77% Upside)
Insider Transactions
Bought Shares
Worth $45.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.54%
12-Months-Change
Fundamentals
Return on Equity
-66.23%
Trailing 12-Months
Asset Growth
-9.82%
Trailing 12-Months
Company Description
Oxford BioMedica plc
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
OXBDF Company Deck
OXBDF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant revenue growth, increased client orders, operational efficiency improvements, and strategic expansions. However, challenges such as the operating EBITDA loss and negative working capital movement were noted.Read More>OXBDF Stock 12 Month Forecast
Average Price Target
$8.81
▲(99.77%Upside)
Technical Analysis
Avacta Group plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Oxford Nanopore Technologies PLC
―